CD19-Targeted MAbs in Relapsed/Refractory DLBCL
CD19-Targeted CAR T-Cell Therapy in Managing DLBCL
Current Treatment Approach to Relapsed/Refractory DLBCL
Targeting CD19 in Diffuse Large B-Cell Lymphoma
Experts in the management of diffuse large B-cell lymphoma (DLBCL) discuss the use of novel CD19-antibody mono- and combination therapies to treat relapsed/refractory subpopulations.
Case 4: Looking Forward in BRCA+ Metastatic TNBC
Case 3: Atezolizumab/Nab-Paclitaxel for Triple Negative Breast Cancer
Case 2: Choosing a CDK4/6 Inhibitor in ER+ Breast Cancer
Case 1: Approach to Early Stage, HER2+ Breast Cancer
Case 4: Chemotherapy or PARP inhibitors for BRCA+ TNBC
Case 4: PARP Inhibitors for Treating BRCA+ Triple-Negative Breast Cancer
Case 4: OlympiAD Trial for BRCA+ Metastatic TNBC
Case 4: BRCA+ Metastatic Breast Cancer
Case 3: Treatment After Progression in Triple-Negative Breast Cancer
Case 3: Managing Immune-Related Adverse Effects in TNBC
Case 3: PD-L1 Testing Used in Triple-Negative Breast Cancer
Case 3: The Use of Combination Therapy in Triple-Negative Breast Cancer
Case 3: Results of the IMpassion130 Trial in Metastatic Breast Cancer
Case 3: Metastatic Triple-Negative Breast Cancer
Case 2: CDK4/6 Inhibitor Recommendations in ER+ Breast Cancer
Case 2: Defining Strongly Versus Less Strongly ER+ Breast Cancer
Case 2: Treatment Recommendations for ER+ Breast Cancer
Case 2: CDK4/6 Inhibitors in ER+ Breast Cancer
Case 2: ER+ Breast Cancer
Case 1: Adjuvant Therapy for Residual Disease in HER2+ Breast Cancer
Case 1: Treatment for Early-Stage HER2+ Breast Cancer
Case 1: Clinical Trials in Early-Stage HER2+ Breast Cancer
Case 1: When to Use FISH Testing in Breast Cancer
Case 1: Guidelines for HER2 Testing in Breast Cancer
Case 1: Decision Making in Early Stage HER2+ Breast Cancer
Case 1: Early-Stage HER2+ Breast Cancer